ATRC at a glance
AtriCure, Inc. (ATRC, SEC CIK 1323885) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on July 27, 2026, an 8-K current report on July 23, 2026 and Form 4 insider filings as recently as September 24, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), AtriCure, Inc. (ATRC) reported revenue of $534.5 million (up 14.9% from FY2024) and a net loss of $11.4 million. Diluted EPS was -$0.24.
- As of June 30, 2026, 33 institutional investment managers tracked by SignalX reported holding AtriCure, Inc. (ATRC) shares worth $534.1 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Privitera Salvatore on September 23, 2026 of 4,519 shares at $60.00 per share.
- In the last 90 days, ATRC insiders reported 0 open-market purchases ($0) and 10 open-market sales ($3.3M) on Form 4, a net sale of $3.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $534.5M
- +14.9% vs prior year
- Insiders · 90 days
- 0 buys · 10 sells
- Net −$3.3M
- 13F holders
- 33 funds
- $534.1M · +0 vs prior quarter
- Latest 8-K
- Jul 23, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model centers on medical devices for cardiac surgery and related treatments
- Enhanced emphasis on cybersecurity risk management aligning with NIST Cybersecurity Framework and Zero Trust principles this fiscal year
- Integration of cybersecurity risk assessments into enterprise risk management with Board oversight introduced or strengthened
- Annual reviews of third-party service providers’ SOC 1 and SOC 2 reports to manage supply chain cybersecurity risks
- Noteworthy focus on potential material adverse effects of cybersecurity incidents on business and financial outcomes
Risk Factors
- No specific or timely regulatory or legal risks detailed beyond general cybersecurity oversight frameworks
- No geopolitical or macroeconomic threats identified with concrete exposure details
- Cybersecurity risk management reliant on a limited IT leadership team with combined 60 years experience, potential expert concentration risk
- No competitive or market disruption risks mentioned involving named competitors or new technology
- No financial or structural risks such as leverage, concentration, or key-person dependencies explicitly highlighted
Management Discussion & Analysis
- Revenue $534.5M, up 14.9% YoY ($465.3M in 2024); growth driven by pain management (+32.5%), open ablation (+16.3%), appendage management (+17.5%), minimally invasive ablation declined (−31.2%)
- Gross margin 75.0% vs 74.7%, up 29 basis points; operating margin loss improved to −1.8% vs −8.6%; net loss narrowed to $11.4M (−2.1%) vs $44.7M (−9.6%)
- Best segment: Appendage management revenue $178.1M, +17.5% YoY; worst: Minimally invasive ablation $31.5M, down 31.2%
- Operating cash flow increased by $45.1M; financing inflows include $6.25M sale-leaseback; cash $167.4M; debt $61.9M with $61.9M borrowing capacity; capex ongoing for facility expansion
- Management expects continued product innovation, clinical trial progress (LeAAPS, BoxX-NoAF), monitors inflation risks, and maintains liquidity via credit facility and shelf registration
AI summary of the ATRC 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No material changes to risk factors from December 31, 2025 Form 10-K
- Regulatory and compliance risks remain those incorporated from the 2025 Form 10-K
- Operational and competitive risks remain those incorporated from the 2025 Form 10-K
- Financial risks remain those incorporated from the 2025 Form 10-K
AI summary of the ATRC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results release for quarter ended June 30, 2026
- Conference call scheduled July 23, 2026 at 4:30 p.m. Eastern Time
Item EX-99.1: Item EX-99.1
- Q2 revenue $153.6M, up 12.8% YoY, led by U.S. pain management and appendage management products
- GAAP net income $9.0M versus $6.2M loss, with diluted EPS $0.18 versus $(0.13)
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Stockholders approved 2023 Plan expansion from 4,500,000 to 6,000,000 shares
- 1,500,000 additional shares increase potential equity-based dilution
Item 5.07: Submission of Matters to a Vote of Security Holders
- All nine director nominees elected to one-year terms ending at the 2027 annual meeting
- Deloitte & Touche ratified as independent auditor for fiscal 2026, with 43,617,566 votes supporting
Item 2.02: Results of Operations and Financial Condition
- Q1 2026 financial results for quarter ended March 31, 2026
- Corrected earnings press release furnished as Exhibit 99.1
AI summaries of ATRC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ATRC
Don't miss the next ATRC filing
- Alerts as it files. A push when ATRC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ATRC, by share count.
- Ask anything. An AI agent that reads every ATRC filing and answers with sources.
ATRC alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Privitera Salvatore | Sell | Sep 23, 2026 | 4,519 | $60.00 |
| GROVES REGINA E | Sell | Sep 11, 2026 | 5,313 | $54.22 |
| Privitera Salvatore | Sell | Sep 8, 2026 | 3,657 | $55.00 |
| Privitera Salvatore | Sell | Sep 2, 2026 | 7,763 | $52.50 |
| Dahlquist Karl S. | Sell | Aug 24, 2026 | 9,370 | $48.89 |
| Prange Karen | Sell | Aug 5, 2026 | 3,564 | $38.80 |
| Yuen Maggie | Sell | Aug 5, 2026 | 3,500 | $38.42 |
| CARREL MICHAEL H | G | Jul 30, 2026 | 700 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $465.3M | $534.5M |
| Gross Profit | - | $347.5M | $400.8M |
| Operating Income | - | -$40.0M | -$9.4M |
| Net Income | - | -$44.7M | -$11.4M |
| Gross Margin | - | 74.7% | 75.0% |
| Op. Margin | - | -8.6% | -1.8% |
| Net Margin | - | -9.6% | -2.1% |
| Balance Sheet | |||
| Total Assets | $613.9M | $609.3M | $654.2M |
| Equity | $466.2M | $461.0M | $491.9M |
| ROE | - | -9.7% | -2.3% |
| Per Share | |||
| EPS | - | $-0.95 | $-0.24 |
| Cash Flow | |||
| Operating CF | - | $12.2M | $57.3M |
| CapEx | - | $11.5M | $9.1M |
Source: XBRL data in AtriCure, Inc. (ATRC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ATRC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 33 | $534.1M |
| Q1 2026 | 33 | $506.1M |
| Q4 2025 | 29 | $630.1M |
| Q3 2025 | 31 | $564.6M |
| Q2 2025 | 29 | $518.8M |
| Q1 2025 | 25 | $416.0M |
| Q4 2024 | 22 | $312.2M |
| Q3 2024 | 18 | $122.8M |
- BlackRock+431.9K (+11%)
- Vanguard Portfolio Management LLC+424.6K (+16%)
- AQR Capital Management+357.7K (+192%)
- FMR LLC (Fidelity)+169.5K (+50%)
- D.E. Shaw & Co+136.2K (+241%)
- Morgan Stanley−261.4K (-36%)
- Two Sigma Investments−225.2K (-30%)
- Renaissance Technologies LLC−74.6K (-24%)
- Goldman Sachs Group−69.2K (-4%)
- Prudential Financial−21.8K (-72%)
- Allstate+21.9K
- Millennium Management−179.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 220 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ATRC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 24, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 10-Q | Jul 27, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 23, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | May 22, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 20, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
- SKIN · Beauty Health CoSurgical & Medical Instruments & Apparatus
ATRC SEC filings: frequently asked questions
Are ATRC insiders buying or selling?
In the last 90 days, AtriCure, Inc. (ATRC) officers, directors and 10% owners reported no open-market purchases and 10 open-market sales worth $3.3 million by 8 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ATRC stock?
As of June 30, 2026, the largest AtriCure, Inc. (ATRC) holders among the 13F filers tracked by SignalX were BlackRock ($125.2 million), Vanguard Portfolio Management LLC ($87.5 million), Vanguard Capital Management LLC ($61.3 million), Goldman Sachs Group ($44.7 million), State Street Corp ($38.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ATRC's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), AtriCure, Inc. (ATRC) reported revenue of $534.5 million (up 14.9% from FY2024) and a net loss of $11.4 million. Diluted EPS was -$0.24. The figures come from the XBRL data in the 10-K.
What are the main risks in ATRC's latest 10-K?
In the 10-K filed February 19, 2026, AtriCure, Inc. (ATRC) flagged: No specific or timely regulatory or legal risks detailed beyond general cybersecurity oversight frameworks. No geopolitical or macroeconomic threats identified with concrete exposure details. (AI summary of the Risk Factors section.)
What did ATRC report in its latest 8-K?
AtriCure, Inc. (ATRC) filed an 8-K on July 23, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results release for quarter ended June 30, 2026.
What are the latest ATRC SEC filings?
AtriCure, Inc. (ATRC) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on July 27, 2026, an 8-K current report on July 23, 2026 and a Form 4 insider filing on September 24, 2026.
What is ATRC's SEC CIK number?
AtriCure, Inc. (ATRC)'s SEC Central Index Key (CIK) is 1323885. EDGAR lists every ATRC filing under that number.
Ask anything about ATRC
The research agent reads ATRC's filings, financials, insider trades and 13F holders, then answers with sources.